Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...
Atherosclerosis represents a chronic inflammatory disease characterized by the accumulation of lipid-laden macrophage foam cells within arterial walls, serving as the underlying pathological basis for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results